1 / 3

EVEREST II

EVEREST II. Study Design Multicenter Randomized in a 2:1 ratio to either percutaneous or conventional surgery for the repair or replacement of the mitral valve (MV) 273 patients with moderately severe or severe (grade 3+ or 4+) mitral regurgitation (MR) Primary Composite Endpoint

keala
Download Presentation

EVEREST II

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. EVEREST II Study Design • Multicenter • Randomized in a 2:1 ratio to either percutaneous or conventional surgery for the repair or replacement of the mitral valve (MV) • 273 patients with moderately severe or severe (grade 3+ or 4+) mitral regurgitation (MR) Primary Composite Endpoint • Efficacy defined as freedom from death, surgery for MV dysfunction, and grade 3+ or 4+ MR at 12 months Primary Safety Endpoint • A composite of major adverse events within 30 days

  2. EVEREST II Results • 55% efficacy in the percutaneous repair group vs 73% in the surgery group (p=0.007) • No difference in mortality rates (6% for both groups • Surgery, MV repair was 20% in the percutaneous group vs 2% in the surgery group (p<0.001) • Grade 3+ or 4+ mitral regurgitation was similar (21% in the percutaneous group vs 20% in the surgery group) • The rate of major adverse events at 30 days was 15% in the percutaneous group vs 48% in the surgery group (p<0.001) Primary Effectiveness at 1and 2 Years

  3. EVEREST II Conclusions • Year 1 results showed that percutaneous repair was less effective at reducing MR than conventional surgery but that the procedure was associated with superior safety and similar improvements in clinical outcomes • Year 2 results demonstrate overall stability in outcomes over the second year of follow-up and no device failures were observed over this period • Longer-term follow-up information will be helpful in assessing the durability of catheter-based MV repair

More Related